NasdaqGM - Nasdaq Real Time Price USD
Axsome Therapeutics, Inc. (AXSM)
104.10
-2.15
(-2.02%)
At close: June 13 at 4:00:01 PM EDT
103.85
-0.25
(-0.24%)
After hours: June 13 at 4:08:49 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 89,800 | 4 |
| Sales | 91,173 | 5 |
| Net Shares Purchased (Sold) | -1,373 | 9 |
| Total Insider Shares Held | 8.09M | -- |
| % Net Shares Purchased (Sold) | -0.00% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| JACOBSON MARK L Chief Operating Officer | Sale at price 110.44 per share. | Direct | 2,761,000 | Jun 9, 2025 |
| JACOBSON MARK L Chief Operating Officer | Conversion of Exercise of derivative security at price 8.02 per share. | Direct | 200,500 | Jun 9, 2025 |
| COLEMAN MARK H Director | Sale at price 103.43 - 105.47 per share. | Direct | 783,375 | May 28, 2025 |
| JACOBSON MARK L Chief Operating Officer | Sale at price 103.45 - 104.66 per share. | Direct | 4,232,636 | May 28, 2025 |
| JACOBSON MARK L Chief Operating Officer | Conversion of Exercise of derivative security at price 6.47 per share. | Direct | 263,154 | May 28, 2025 |
| COLEMAN MARK H Director | Sale at price 107.49 per share. | Direct | 322,473 | May 20, 2025 |
| PIZZIE NICK Chief Financial Officer | Sale at price 129.86 - 131.07 per share. | Direct | 1,951,530 | Feb 14, 2025 |
| PIZZIE NICK Chief Financial Officer | Conversion of Exercise of derivative security at price 3.50 per share. | Direct | 52,500 | Feb 14, 2025 |
| COLEMAN MARK H Director | Conversion of Exercise of derivative security at price 9.00 per share. | Direct | 82,143 | Jan 3, 2025 |
| COLEMAN MARK H Director | Conversion of Exercise of derivative security at price 5.94 per share. | Direct | 198,455 | Nov 19, 2024 |
| SAAD MARK E Director | Sale at price 91.31 per share. | Direct | 1,005,871 | Sep 11, 2024 |
| SAAD MARK E Director | Conversion of Exercise of derivative security at price 3.67 per share. | Direct | 40,429 | Sep 11, 2024 |
| JACOBSON MARK L Chief Operating Officer | Sale at price 84.26 per share. | Direct | 4,022,488 | Aug 9, 2024 |
| JACOBSON MARK L Chief Operating Officer | Conversion of Exercise of derivative security at price 4.04 per share. | Direct | 192,866 | Aug 9, 2024 |
| COLEMAN MARK H Director | Sale at price 75.14 - 75.21 per share. | Direct | 789,107 | May 29, 2024 |
| JACOBSON MARK L Chief Operating Officer | Sale at price 74.31 per share. | Direct | 587,813 | May 29, 2024 |
| JACOBSON MARK L Chief Operating Officer | Conversion of Exercise of derivative security at price 1.30 per share. | Direct | 17,801 | May 29, 2024 |
| JACOBSON MARK L Chief Operating Officer | Sale at price 77.24 per share. | Direct | 1,904,942 | Apr 1, 2024 |
| JACOBSON MARK L Chief Operating Officer | Conversion of Exercise of derivative security at price 1.30 per share. | Direct | 32,061 | Apr 1, 2024 |
| JEFFS ROGER A Director | Sale at price 69.70 - 71.61 per share. | Direct | 2,257,449 | Mar 15, 2024 |
| JEFFS ROGER A Director | Conversion of Exercise of derivative security at price 22.03 - 29.91 per share. | Direct | 789,986 | Mar 15, 2024 |
| COLEMAN MARK H Director | Sale at price 75.18 - 75.19 per share. | Indirect | 2,224,430 | Sep 15, 2023 |
| COLEMAN MARK H Director | Conversion of Exercise of derivative security at price 3.67 per share. | Direct | 40,429 | Sep 15, 2023 |
Related Tickers
MDGL Madrigal Pharmaceuticals, Inc.
295.57
-0.55%
TGTX TG Therapeutics, Inc.
36.01
-3.64%
BBIO BridgeBio Pharma, Inc.
39.78
+0.33%
VRNA Verona Pharma plc
92.20
-0.32%
IOVA Iovance Biotherapeutics, Inc.
2.2400
-3.03%
VKTX Viking Therapeutics, Inc.
26.08
-8.75%
AKRO Akero Therapeutics, Inc.
55.62
+3.85%
ALT Altimmune, Inc.
6.92
-3.22%
CYTK Cytokinetics, Incorporated
34.38
+3.55%
URGN UroGen Pharma Ltd.
12.03
+8.57%